Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 6Breast Neoplasms 6Endometrial Neoplasms 4Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms by Site 1Mesothelioma 1Lymphoma 1Leukemia 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Head and Neck Neoplasms 1ER+ HER2- Advanced Breast Cancer 1Digestive System Neoplasms 1Carcinosarcoma 1Breast Diseases 1Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 6Paclitaxel 6Magnetic Resonance Spectroscopy 5Nivolumab 4Carboplatin 4Biopsy 4pembrolizumab 2olaparib 2ceralasertib 2Taxes 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1ribociclib 1rebastinib 1pelcitoclax 1pamiparib 1durvalumab 1cobimetinib 1cediranib 1cabozantinib 1belinostat 1atezolizumab 1X-Rays 1Tissue Banks 1TIC10 compound 1Ipilimumab 1Immunoglobulin G 1Ifosfamide 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × ribociclib × Gynecologic × Clear all
NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Blueprint Medicines Corporation

Phase 1 Terminated
50 enrolled
GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡